Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Acq. announced
Director departure
CC transcript
Inv. presentation
Jazz Pharmaceuticals plc (JAZZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance – Strong execution delivered second quarter 2023 total revenues of $957 million –"
07/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2023 ARS Form ARS - Annual Report to Security Holders:
06/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance Focus on commercial execution drove 1Q23 total revenues of $892.8 million"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021"
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.6% stake in Jazz Pharmaceuticals plc
01/20/2023 SC 13G BlackRock Inc. reports a 10.6% stake in JAZZ PHARMACEUTICALS PLC
01/09/2023 8-K Investor presentation
Docs: "Presentation slides by Jazz Pharmaceuticals plc on January 9, 2023",
"Presentation slides by Jazz Pharmaceuticals plc on January 9, 2023"
01/05/2023 SC 13G/A JPMORGAN CHASE & CO reports a 4.6% stake in JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
01/04/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/21/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy